Moderna just moved one step closer to bringing mRNA-1345, an RSV shot, to market
The U.S. Food and Drug Administration granted the experimental shot fast-track designation in August 2021
Now, Modernas mRNA RSV shot has been given Breakthrough Therapy Designation, which allows for faster development and an expedited review period
RSV is usually not serious; most people experience only mild, cold-like symptoms and recover on their own in a week or two
Moderna plans to file for FDA approval of mRNA-1345 in the first half of 2023
Along with Modernas mRNA RSV shot, Pfizer and GSK have also developed RSV vaccines that are awaiting regulatory approval
Poster Comment:
They also are approving mRNA vaxxes for animals.